Sunil Badve

Nephrologist, Conjoint Professor of Medicine @UNSWMedicine @georgeinstitute. 'Science is a way of thinking much more than it is a body of knowledge.' Carl Sagan

[Sunil Badve @Badves]

Excited to share our latest study showing kidney, CV and survival benefits of GLP-1 receptor agonists just published in @TheLancetEndo Time-limited free access https://t.co/skhqzkBvVg
1/

[Eric Weinhandl @eric_weinhandl]

The most important figure in the new USRDS Annual Data Report. #KidneyWk

[Brendon Neuen @brendonneuen]

Colleagues, we need your help -

We're seeking nephrologists' perspectives on management of iron deficiency in CKD. The survey takes <5 minutes & will help shape the design of a new international randomised trial

https://t.co/T9G4ILLL70

Thanks for sharing with your networks

[AHA Science @AHAScience]

📣Announcing #ScientificSessions26 Late-Breaking Science.

Join us in November to experience the highest tier of scientific discovery and practice-changing educational content.

📍Chicago, Nov 6-9

@JoChikweMD @bnallamo

[Andreas Kronbichler @AKronbichler]

Please see our review on unmet needs in the management of lupus nephritis - aiming for a balanced view

https://t.co/kPBPj6ubz6

[Edgar V. Lerma 🇵🇭 @edgarvlermamd]

Theoretical Distribution of intravenous fluids (IVFs) on infusion from @will_s_t @bmj_latest
#Nephpearls #AKIinICU

👉 https://t.co/RChEpYPgwy

[glomcon @GlomCon]

⏳🚨 A quick summary of the latest IgAN developments by @VladoPerkovic

@goKDIGO updates from glomcon Hawaii 2026

https://t.co/vX0MgLkA1E

[Sunil Badve @Badves]

@AgarwalRajivMD Congratulations Rajiv

[Sunil Badve @Badves]

@gunnar_heine @AKronbichler @MarkusAtHome @hjanders_hans @NDTsocial Congratulations @AKronbichler

[Sandhya Suresh @Sandyrvsdav]

@ISNeducation @ISNkidneycare @KajareeG @krithicism @myadla The conversation now shifts to #LupusNephritis by Prof Brad Rovin @BradRovin

A recent KDIGO Controversies Conference highlighted rapidly expanding B-cell therapeutic landscape

3 concepts reshaping the future of LN therapy
➡️Deep B-cell depletion
➡️Immune reset
➡️Disease cure

[Sandhya Suresh @Sandyrvsdav]

@ISNeducation @ISNkidneycare @KajareeG @krithicism @myadla @BradRovin Obinutuzumab, a type II anti-CD20 antibody, achieved deeper and more sustained peripheral and tissue B-cell depletion than rituximab, translating into improved renal responses in LN

Perhaps it's not just B-cell depletion, but how completely we deplete them

[NEJM @NEJM]

Presented at #ERA26:

In adults without diabetes who had chronic kidney disease, the nonsteroidal mineralocorticoid receptor antagonist finerenone led to a slower decrease in the estimate glomerular filtration rate than placebo over 32 months. Full phase 3 FIND-CKD trial results: https://t.co/BSF1GmHFaf

@ERAkidney

[Brendon Neuen @brendonneuen]

Now online: The largest global validation of AHA PREVENT & ESC SCORE2 cardiovascular risk tools. Across ~6.5M people, both performed comparably across geographies & albuminuria further improved risk prediction

Open access in @NatureMedicine:
https://t.co/HiSjXc01rI

[SpaceX @SpaceX]

Three years since the first flight of Starship, the next generation is here. New ship. New booster. New engines. New pad and new test site. SpaceX engineers are working to solve one of the most difficult engineering challenges in history: developing a fully, rapidly reusable rocket

[Sunil Badve @Badves]

@eric_weinhandl Considering the short follow up of the trial, the effect size is actually quite impressive.

[C. Michael Gibson MD @CMichaelGibson]

Dr. Mike Sharma and I discuss the results of the phase III OCEANIC-STROKE Trial: In secondary stroke prevention the Factor Xi inhibitor Asundexian reduced the risk of recurrent ischemic stroke at 1 year by 26%. The absolute reduction was such that only 53 people would we need to be treated to prevent another stroke at 1 year.

There was no increase in mild or severe bleeding or intracranial bleeding

63% of people were on DAPT at study start, and they had the same benefit as people on antiplatelet monotherapy
Similar benefit in medium to large vessel ischemic stroke, lacunar stroke and stroke of unidentified origin

All benefit with no increase in bleeding risk

View slides here: https://t.co/mk0BVUGhEY

[Daniel Coyne @DrDanMO]

I’m not surprised the manuscript was accepted. It’s so believable!

[Joel M. Topf, MD FACP @kidney_boy]

Scientists found a way to reverse kidney damage—is a cure next? - National Geographic

It's about the 4-pillar approach to CKD with Kathleen Tuttle, Vlado Perkovic, and Prabir Roy-Chaudhury, among others https://t.co/s1iKQRLOns

[Roger Rodby @NephRodby]

@SabeloShezi_ Cystatin C is normal. He does not have CKD
Cr in the blood reflects production (muscle mass dependent) & GFR. Think of cystatin C as a muscle mass ignorant Cr level. Most creatine OTC formulations do not increase Cr contrary to popular belief, Kid Int (2019) 96, 527–528

[KDIGO @goKDIGO]

KDIGO is pleased to share the newly published report from its Controversies Conference on Preventing CKD and Maintaining Kidney Health, now available in press in @Kidney_Int.

📄Download the report: https://t.co/gEVKYm5mG6
📘 Read the report in KI: https://t.co/RdWDEpz3Mo

Co-chaired by Dr. Alberto Ortiz and Dr. Kathy Tuttle, the conference brought together global experts and patient advocates to reframe how kidney disease is addressed, prioritizing prevention, early detection, and long-term kidney health across the lifespan.

“CKD affects over 800 million people worldwide and is one of the major unsolved challenges in global health,” said Dr. Ortiz. “We need structural changes that support proactive primary prevention in addition to earlier diagnosis and treatment—especially in low- and middle-income countries.”

“The data now show that kidney disease is not inevitable. In many cases, it can be delayed—or even prevented—if we intervene early," said Dr Tuttle. "We need to treat CKD prevention as a public health priority, like we’ve done for heart disease and diabetes. That means integrating kidney health into the entire continuum of chronic disease prevention and empowering both clinicians and patients through education and awareness.”

#kidneyhealth #publichealth #CKD

[The IMJ @The_IMJ]

IMJ June 2025 #FreeAccess
Editorial: Smokers and kidney transplantation assessment: a question of risk or equity?
https://t.co/u7345Eo43y
@TheRACP @WileyHealth @Badves